Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOLR IND

This article was originally published in The Tan Sheet

Executive Summary

Bellevue, Wash.-based firm has submitted an investigational new drug application with FDA in advance of conducting studies on extended-release ibuprofen in humans, the firm announces. The trial is slated to begin in early 2005, with an NDA submission planned for the summer, SCOLR adds. The firm initially aimed to begin human trials in Canada this fall (1"The Tan Sheet" Aug. 2, 2004, p. 12)...

You may also be interested in...



Ibuprofen Extended-Release NDA Slated For 2005, SCOLR Pharma Says

SCOLR Pharma plans to file an NDA in summer 2005 for CDT extended-release 12-hour ibuprofen tablets, the firm announced July 26

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Blueprint Medicines' Ayvakyt for treating unresectable or metastatic gastrointestinal stromal tumors. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).

EU Biosimilar Filings, Opinions And Approvals

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel